A 79-year-old white man with a history of progressive bone pain was admitted for evaluation 3 years ago. The patient reported that the pain began in both feet and gradually spread to the rest of the body over a 2-year period. Further assessment revealed multiple stress fractures in the feet. Bone mineral density test indicated osteopenia. Serial bone mineral density tests during the 2 years showed that his osteopenia was progressing. Results of several serum protein electrophoreses were essentially normal. His medical history, which included surgical removal of a cerebral aneurysm near the sella turcica and bacterial meningitis, suggested no pertinent etiologic factors. Physical examination revealed no clinically significant findings except unsteady gait. His serum phosphate concentrations declined from 2.5 to 1.8 mg/dL over the 2 years before admission. Laboratory test results at the time of admission are summarized in Table 1 . The patient's phosphate concentration reached a nadir of 1.2 mg/dL at admission. His serum alkaline phosphatase was increased. Other notable abnormalities included low normal calcium, normal to borderline high parathyroid hormone (PTH), 2 and increased 24-h urine phosphate and calcium excretion. Other routine biochemical parameters [including ionized calcium, thyroid-stimulating hormone, and free thyroxine (T 4 )] were normal. The patient underwent a whole-body scan showing multiple bone lesions. Diagnostic imaging studies including x-ray, a computer axial tomography (CAT), and MRI of the lungs, abdomen, and pelvis were reported to be normal at admission.
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CASE DESCRIPTION
A 79-year-old white man with a history of progressive bone pain was admitted for evaluation 3 years ago. The patient reported that the pain began in both feet and gradually spread to the rest of the body over a 2-year period. Further assessment revealed multiple stress fractures in the feet. Bone mineral density test indicated osteopenia. Serial bone mineral density tests during the 2 years showed that his osteopenia was progressing. Results of several serum protein electrophoreses were essentially normal. His medical history, which included surgical removal of a cerebral aneurysm near the sella turcica and bacterial meningitis, suggested no pertinent etiologic factors. Physical examination revealed no clinically significant findings except unsteady gait. His serum phosphate concentrations declined from 2.5 to 1.8 mg/dL over the 2 years before admission. Laboratory test results at the time of admission are summarized in Table 1 . The patient's phosphate concentration reached a nadir of 1.2 mg/dL at admission. His serum alkaline phosphatase was increased. Other notable abnormalities included low normal calcium, normal to borderline high parathyroid hormone (PTH), 2 and increased 24-h urine phosphate and calcium excretion. Other routine biochemical parameters [including ionized calcium, thyroid-stimulating hormone, and free thyroxine (T 4 )] were normal. The patient underwent a whole-body scan showing multiple bone lesions. Diagnostic imaging studies including x-ray, a computer axial tomography (CAT), and MRI of the lungs, abdomen, and pelvis were reported to be normal at admission.
Based on the above findings, the patient was diagnosed with osteomalacia secondary to hypophosphatemia. He was then treated with several medications, including bisphosphonates, calcitriol, vitamin D, and calcium and phosphorus supplements. Vitamin D was given because his initial calcium and phosphate concentrations were low, and it was discontinued later following improvement of serum calcium concentrations. Despite substantial phosphorus replacement (250 mg phosphorus per tablet, 2 tablets 3 times a day), the hypophosphatemia continued, along with bone fragility and muscle weakness over the next 3 years, and his height decreased from 173 to 163 cm.
DISCUSSION
The patient was evaluated further by several physicians from different disciplines 3 years after the first admission. This evaluation revealed extensive bone lesions and multiple rib fractures consistent with osteomalacia. In addition, he was found to have a soft tissue mass on the left posterior 10th rib, and computed tomography (CT) scan revealed cortical destruction of this rib. Follow-up MRI showed a mass suggesting expansile hemangiopericytoma of the left posterior thorax. CTguided fine-needle aspiration biopsy and histologic evaluation of the sample confirmed hemangiopericytoma. His plasma concentration of fibroblast growth factor 23 (FGF23) was increased (292 RU/mL; reference interval Յ180 RU/mL). A diagnosis of hemangiopericytoma with secondary tumor-induced osteomalacia and hypophosphatemia was made based on the above findings. The patient underwent resection, and a mass of approximately 8 ϫ 4 cm involving predominantly the left 10th rib, with extension into the 9 -10 interspace and into the posterior paraspinal musculature, was removed. Immunohistochemical staining revealed that FGF23 was highly overexpressed in the tumor tissue. Since excision of the tumor, the patient has had complete reversal of his metabolic abnormalities in 2 months. His phosphate and calcium concentrations normalized; he no longer requires any calcium, vitamin D, or phosphorus supplementation; and his motor strength is improving. His overall well-being has improved greatly. His bone density is improving. These improvements are consistent with the literature indicating that serum phosphate returns to normal by postoperative day 5 but some patients may take as long as 10 days. Most patients feel better within days to weeks of tumor removal. Bone healing starts immediately, but it may take up to a year or more for clinically significant clinical improvement (1 ) .
Phosphate is an important element for cellular functions, bone development, and mineralization. Hypophosphatemia is defined as a serum phosphate concentration Ͻ2.5 mg/dL. A serum phosphate concentration Ͻ1.5 mg/dL is considered severe hypophosphatemia and typically results in clinical signs and symptoms (2 ) . Chronic hypophosphatemia can be induced by decreased phosphate intake; increased renal phosphate wasting due to primary or secondary hyperparathyroidism or a renal tubular defect causing decreased renal phosphate absorption and increased excretion; unusual loss from the gastrointestinal tract caused by diarrhea, malabsorption, or vitamin D deficiency; and tumor (2 ) .
Diet is the primary source of phosphate, but inadequate phosphate intake alone is not a common cause of hypophosphatemia. It is generally recognized that PTH and vitamin D are the key regulators of phosphate metabolism. However, several novel regulators of phosphate homeostasis have been identified as being associated with hypophosphatemia of various types, such as tumor-induced osteomalacia, several hereditary forms of hypophosphatemic rickets, X-linked hypophosphatemia, and autosomal dominant hypophosphatemia (1, 3 ) . Oncogenic hypophosphatemia is a rare cause of severe hypophosphatemia.
Tumor-induced osteomalacia, also known as oncogenic hypophosphatemic osteomalacia or oncogenic osteomalacia, is a paraneoplastic syndrome that presents with muscle weakness, bone pain, and osteomalacia in association with specific tumors and overexpression of FGF23 (3, 4 ) . Tumor-induced osteomalacia is rare, but when it occurs is most commonly caused by benign phosphaturic mesenchymal tumors among which hemangiopericytoma is the primary one (5 ). It can also be induced by other types of tumors such as carcinomas, sarcomas, neurofibromatosis, bone neoplasms, and pseudotumors (4, 6 ) . Most of these tumors are benign, but they have malignant potential. Tumor-induced osteomalacia has revealed novel aspects of endocrine interactions among the skeleton, the kidney, and the parathyroid glands. Clinical signs in adults include worsening myalgias, bone pain, and fatigue; as the condition progresses, recurrent fractures are common. Children present with difficulty in walking, stunted growth, and rickets (3 ) .
Because most of the tumors are benign and grow slowly, and the symptoms are nonspecific, identification and localization of the tumor is difficult. The typical time from the onset of symptoms to a presumptive diagnosis of tumor-induced osteomalacia often exceeds 2.5 years, and the mean time from then until the responsible tumor is identified is approximately 5 years (3 ). In our case, several factors may have caused the delay of the diagnosis. For example, the early diagnostic imaging studies including x-ray, CAT scan, and MRI of the lungs, abdomen, and pelvis were reported to be normal at admission. Initial bone osteomalacia was diagnosed and treated, but no definitive cause was identified. A diagnosis of lymphoma made the doctors suspect that the patient's hypophosphatemic osteomalacia was likely due to Fanconi syndrome caused by the lymphoma. However, no improvement was achieved in his symptoms and clinical findings after chemotherapy and complete remission of lymphoma.
The mechanism of tumor-induced osteomalacia is thought to be related to increased secretion of FGF23. The FGF23 gene is expressed at very low concentrations in normal tissue but at very high concentrations in tumors associated with osteomalacia (3, 7 ) . FGF23 is a (2, 3, 8, 9 ). Evidence suggests that increased FGF23 concentrations occur even in early stages of chronic kidney disease (2 ) and may contribute to tissue damage in individuals with chronic renal failure. The characteristic biochemical phenotype is hypophosphatemia, hyperphosphaturia, normal or low serum calcium, increased serum alkaline phosphatase, normal or increased serum PTH, normal serum 25-hydroxyvitamin-D, and low or normal serum 1,25-dihydroxyvitamin-D (9, 10 ) . In our case, we did not see very low serum 1,25-dihydroxyvitamin D results. First, the patient had been given vitamin D, which may raise 1,25-dihydroxyvitamin D to some extent. Second, FGF23 was not very high, which may compromise the inhibitory potential. Third, 1,25-dihydroxyvitamin D is also regulated by PTH and the PTH concentration was relatively high in our case. Fourth, in comparison to the results after surgical removal of the tumor, serum 1,25-dihydroxyvitamin D concentration was lower before surgery (42 vs 56 pg/mL), suggesting that there was an inhibition of 1,25-dihydroxyvitamin D to some extent. Our 1,25-dihydroxyvitamin D results are consistent with those from other case studies (7) (8) (9) (10) .
Besides the causes of hypophosphatemia already outlined, other clinical entities that result in progressive weakness, bone and muscle pain, and fractures should be included in the differential diagnosis. X-linked hypophosphatemia and autosomal dominant hypophosphatemia are biochemically indistinguishable from tumor-induced osteomalacia; genetic testing for the PHEX (phosphate-regulating gene with homologies to endopeptidase on the X-chromosome) and FGF23 genes will identify patients with X-linked hypophosphatemia and autosomal dominant hypophosphatemia, respectively (1, 3, 9, 10 ) .
In conclusion, tumor-induced osteomalacia is a rare pathologic disorder that presents with muscle weakness, bone pain, hypophosphatemia, and osteomalacia. Tumor-induced osteomalacia is usually caused by a benign mesenchymal tumor, and complete remission can be achieved by tumor resection. In addition to other biochemical measurements including serum phosphate, alkaline phosphatase, PTH, and vitamin D and urine phosphate, earlier ordering of serum FGF23 would reduce the delay and contribute to less morbidity for patients with this disease. 
POINTS TO REMEMBER
• Chronic hypophosphatemia can be induced by decreased phosphate intake; increased renal phosphate wasting due to primary or secondary hyperparathyroidism or a renal tubular defect causing decreased renal phosphate absorption and increased excretion; unusual loss from the gastrointestinal tract caused by diarrhea, malabsorption, or vitamin D deficiency; and tumor.
• Tumor-induced osteomalacia is a paraneoplastic syndrome that presents with muscle weakness, bone pain, hypophosphatemia, and osteomalacia in association with specific tumors and overexpression of FGF23. FGF23 inhibits renal tubular phosphate reabsorption and renal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, leading to the biochemical and skeletal abnormalities.
• Patients with tumor-induced osteomalacia are characterized biochemically by hypophosphatemia, hyperphosphaturia, inappropriately low or normal 1,25-dihydroxyvitamin D concentration, and increased alkaline phosphatase concentration.
• The diagnosis of tumor-induced osteomalacia can be challenging. Localization of the tumor can be difficult, as it typically grows slowly. Measurement of serum phosphorus is important in patients with persistent musculoskeletal symptoms. A strategy of combined chemistry test panel and imaging approaches may decrease the time between symptom onset and tumor identification.
• Besides routine laboratory tests such as serum phosphate, alkaline phosphatase, PTH, and vitamin D and urine phosphate, serum FGF23 should be ordered when tumor-induced osteomalacia is suspected. Tumorinduced osteomalacia can be differentiated from certain heritable hypophosphatemias (X-linked hypophosphatemia and autosomal dominant hypophosphatemia) by genetic testing.
